Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Acer Shares Down On FDA's CRL For Genetic Disorder Treatment

By Zacks Investment ResearchStock MarketsJun 26, 2019 08:32AM ET
www.investing.com/analysis/acer-shares-down-on-fdas-crl-for-genetic-disorder-treatment-200434836
Acer Shares Down On FDA's CRL For Genetic Disorder Treatment
By Zacks Investment Research   |  Jun 26, 2019 08:32AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Shares of Acer Therapeutics Inc. (NASDAQ:ACER) slumped more than 75% after it received a Complete Response Letter (CRL) from the FDA regarding its new drug application (NDA) for Edsivo (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS). Ehlers-Danlos Syndrome (“EDS”) is an inherited disorder caused by mutations in the genes responsible for the structure, production, or processing of collagen.

In the CRL, the FDA has asked the company to conduct an adequate and well-controlled study to determine whether Edsivo reduces the risk of clinical events in patients with vEDS. Acer plans to request a meeting with the FDA to discuss its response. The company expects to respond to the FDA in the third quarter of 2019. The CRL implies a delay in the approval of Edsivo.

Edsivois a selective adrenergic modulator and is currently approved in the European Union for the treatment of hypertension and angina.

Edsivo has an Orphan Drug exclusivity designation in the United States for the vEDS indication.

The company also has other candidates in its pipeline. Its ACER-001 is a fully taste-masked, immediate release formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders (“UCD”) and Maple Syrup Urine Disease (“MSUD”). The company expects to submit an NDA for ACER-001 in UCD in the fourth quarter of 2019. The company also has osanetant in its pipeline, which is being evaluated for the treatment of various neuroendocrine disorders. An investigational new drug (“IND”) application for the drug is anticipated in the second half of 2019.

Zacks Rank and Stocks to Consider

Acer currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks are Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) , Evotec AG (OTC:EVTCY) and Neos Therapeutics Inc. (NASDAQ:NEOS) , each carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Cumberland’s earnings per share estimates have moved up from 7 cents to 46 cents for 2020 in the past 60 days. The company beat estimates in the trailing four quarters, the average being 137.17%.

Evotec’s earnings per share estimates have moved up from 90 cents to $1.03 for 2019 and from 97 cents to $1.37 for 2020 in the past 60 days.

Neos’ loss per share estimates have narrowed from 66 cents to 61 cents for 2019 in the past 60 days. The company outpaced estimates in two of the trailing four quarters, the average being 2.85%.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>



Neos Therapeutics, Inc. (NEOS): Free Stock Analysis Report

Evotec AG (EVTCY): Free Stock Analysis Report

Cumberland Pharmaceuticals Inc. (CPIX): Free Stock Analysis Report

Opexa Therapeutics, Inc. (ACER): Free Stock Analysis Report

Original post

Zacks Investment Research
Acer Shares Down On FDA's CRL For Genetic Disorder Treatment
 

Is Apple Undervalued?

Based on 15 different premium valuation models, we calculate whether Apple stock is undervalued or overvalued every day. If you are considering Apple for your portfolio, you need to check this out:

See Fair Value Now
Unlock Apple's unbiased fair value with InvestingPro+

Related Articles

Acer Shares Down On FDA's CRL For Genetic Disorder Treatment

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email